Sesen Bio's Bladder Cancer Trial Wrecked By Misconduct: Stat News

by Vandana Singh, Benzinga Editor

August 18, 2021 1:45 PM | 1 min read |

Sesen Bio Inc SESN said that it was not expecting a CRL from the FDA for its bladder cancer candidate Vicineum.
But the rejected filing includes several violations and investigator misconduct, STAT News reported.
Related: Sesen Bio Stock Crashes As FDA Shoots Down Its Bladder Cancer Pitch.
The 130-patient study had more than 2,000 violations, 215 classified as major, STAT reported.
Independent monitors also reported three investigators to the FDA for a “serious noncompliance” that “placed subjects at risk of harm.”
A patient died in 2016 of liver failure related to the drug, and two years later, the company said that there were no drug-related deaths at a urology conference.
Price Action: SESN shares are down 13.6% at $1.30 during the market session on the last check Wednesday.

Posted In: Biotech News Penny Stocks Short Ideas Health Care FDA Movers Trading Ideas General bladder cancer Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.